Literature DB >> 26019434

Refractory status epilepticus from NMDA receptor encephalitis successfully treated with an adjunctive ketogenic diet.

Syed Amer1, Parth Shah2, Vishnu Kommineni2.   

Abstract

Entities:  

Year:  2015        PMID: 26019434      PMCID: PMC4445212          DOI: 10.4103/0972-2327.150620

Source DB:  PubMed          Journal:  Ann Indian Acad Neurol        ISSN: 0972-2327            Impact factor:   1.383


× No keyword cloud information.
Sir, N-methyl D-aspartate receptor encephalitis (NMDARE) is characterized by the presence of NMDAR antibodies in the CSF, and it can progress to psychosis and refractory status epilepticus (RSE). We report a case of the use of a ketogenic diet (KD) as an adjunct in RSE from NMDARE. A healthy 21-year-old female presented to the ED with symptoms that progressed from depression, headaches, and nausea to word-finding difficulties, psychosis, and seizures. She developed SE and was intubated. A comprehensive evaluation was unremarkable, and she was transferred to our institution on hospital day 11 where an electro-encephalogram (EEG) revealed RSE. The NMDAR antibody was detected in her CSF. A thorough investigation was negative for any tumor. Despite corticosteroids, plasmapheresis, IV Ig in addition to 5 anticonvulsant medications and propofol, continuous EEG showed RSE. Ketosis was achieved after a KD (ratio of fat: Combined carbohydrate and protein of 4:1) was started (day 21). Her continuous EEG showed a significant decrease in her seizures within 2 weeks (day 35). She was weaned off mechanical ventilation and discharged to a long-term care facility on 3 anticonvulsant medications, mycophenolate mofetil, and on a KD. Most patients with NMDARE develop a multistage illness that progresses to psychosis, memory deficits, RSE, and into a state of unresponsiveness with catatonic features.[1] Management of NMDARE should initially focus on immunotherapy and the detection and removal of the tumor.[23] Most patients receive corticosteroids, PLEX, or IV Ig as first-line immunotherapy. Additional treatment with second-line cyclophosphamide or rituximab is sometimes needed. Our patient continued to deteriorate despite these therapies. A KD, by reducing the firing of central neurons by opening K ATP channels[4], is a very effective adjunct to antiepileptics in patients with refractory epilepsy. Side effects of KD[5] are usually mild, predictable, and preventable, and rarely lead to diet discontinuation. Important ones include constipation, acidosis, dyslipidemia, kidney stones, and bone fractures. To our knowledge, this is the first case report of initiating a KD as an adjunct in RSE from NMDARE.
  5 in total

1.  Ketogenic diet metabolites reduce firing in central neurons by opening K(ATP) channels.

Authors:  Weiyuan Ma; Jim Berg; Gary Yellen
Journal:  J Neurosci       Date:  2007-04-04       Impact factor: 6.167

Review 2.  Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis.

Authors:  Josep Dalmau; Eric Lancaster; Eugenia Martinez-Hernandez; Myrna R Rosenfeld; Rita Balice-Gordon
Journal:  Lancet Neurol       Date:  2011-01       Impact factor: 44.182

3.  Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies.

Authors:  Josep Dalmau; Amy J Gleichman; Ethan G Hughes; Jeffrey E Rossi; Xiaoyu Peng; Meizan Lai; Scott K Dessain; Myrna R Rosenfeld; Rita Balice-Gordon; David R Lynch
Journal:  Lancet Neurol       Date:  2008-10-11       Impact factor: 44.182

4.  Early- and late-onset complications of the ketogenic diet for intractable epilepsy.

Authors:  Hoon Chul Kang; Da Eun Chung; Dong Wook Kim; Heung Dong Kim
Journal:  Epilepsia       Date:  2004-09       Impact factor: 5.864

5.  Diagnostic value of N-methyl-D-aspartate receptor antibodies in women with new-onset epilepsy.

Authors:  Pitt Niehusmann; Josep Dalmau; Christian Rudlowski; Angela Vincent; Christian E Elger; Jeffrey E Rossi; Christian G Bien
Journal:  Arch Neurol       Date:  2009-04
  5 in total
  6 in total

1.  Phase I/II multicenter ketogenic diet study for adult superrefractory status epilepticus.

Authors:  Mackenzie C Cervenka; Sara Hocker; Matthew Koenig; Barak Bar; Bobbie Henry-Barron; Eric H Kossoff; Adam L Hartman; John C Probasco; David R Benavides; Arun Venkatesan; Eliza C Hagen; Denise Dittrich; Tracy Stern; Batya Radzik; Marie Depew; Filissa M Caserta; Paul Nyquist; Peter W Kaplan; Romergryko G Geocadin
Journal:  Neurology       Date:  2017-02-08       Impact factor: 9.910

Review 2.  Updates in Refractory Status Epilepticus.

Authors:  Rohit Marawar; Maysaa Basha; Advait Mahulikar; Aaron Desai; Kushak Suchdev; Aashit Shah
Journal:  Crit Care Res Pract       Date:  2018-05-08

Review 3.  The role for ketogenic diets in epilepsy and status epilepticus in adults.

Authors:  Tanya J Williams; Mackenzie C Cervenka
Journal:  Clin Neurophysiol Pract       Date:  2017-07-01

4.  Ketogenic Diet for Super-refractory Status Epilepticus: A Case Series and Review of Literature.

Authors:  Sucharita Anand; Amar S Vibhute; Ananya Das; Shilpi Pandey; Vimal Kumar Paliwal
Journal:  Ann Indian Acad Neurol       Date:  2021-02-05       Impact factor: 1.383

Review 5.  Therapeutic Options for Patients with Refractory Status Epilepticus in Palliative Settings or with a Limitation of Life-Sustaining Therapies: A Systematic Review.

Authors:  Laurent M Willems; Sebastian Bauer; Kolja Jahnke; Martin Voss; Felix Rosenow; Adam Strzelczyk
Journal:  CNS Drugs       Date:  2020-08       Impact factor: 5.749

6.  Ketogenic Diet Therapy for the Treatment of Post-encephalitic and Autoimmune-Associated Epilepsies.

Authors:  Khalil S Husari; Mackenzie C Cervenka
Journal:  Front Neurol       Date:  2021-06-16       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.